Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12570MR)

This product GTTS-WQ12570MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12570MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ439MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ7732MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ585MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ356MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ12948MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ14183MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ711MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ12527MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW